Skip to main content

Phase 3 Readout

AMGN: Phase 3 Topline: A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pemb

December 14, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
December 14, 2026
Company
AMGEN INC (AMGN)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pemb

AMGN overview →
Indication
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Other upcoming events for AMGN

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of Apremilast
Phase 2 StartPhase 2 Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safe
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evalu
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effica